CA2777899C - Composition for inhalation comprising a pharmaceutically acceptable glassy matrix - Google Patents

Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Download PDF

Info

Publication number
CA2777899C
CA2777899C CA2777899A CA2777899A CA2777899C CA 2777899 C CA2777899 C CA 2777899C CA 2777899 A CA2777899 A CA 2777899A CA 2777899 A CA2777899 A CA 2777899A CA 2777899 C CA2777899 C CA 2777899C
Authority
CA
Canada
Prior art keywords
composition
metal ion
calcium lactate
ion salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2777899A
Other languages
English (en)
French (fr)
Other versions
CA2777899A1 (en
Inventor
Glen Martyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovata Ltd
Original Assignee
Innovata Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovata Ltd filed Critical Innovata Ltd
Publication of CA2777899A1 publication Critical patent/CA2777899A1/en
Application granted granted Critical
Publication of CA2777899C publication Critical patent/CA2777899C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2777899A 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Active CA2777899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0918450.8 2009-10-21
GBGB0918450.8A GB0918450D0 (en) 2009-10-21 2009-10-21 Composition
PCT/GB2010/001955 WO2011048379A2 (en) 2009-10-21 2010-10-21 Composition

Publications (2)

Publication Number Publication Date
CA2777899A1 CA2777899A1 (en) 2011-04-28
CA2777899C true CA2777899C (en) 2016-03-29

Family

ID=41426476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777899A Active CA2777899C (en) 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix

Country Status (7)

Country Link
US (1) US20130004542A1 (enExample)
EP (1) EP2490670B1 (enExample)
JP (1) JP2013508344A (enExample)
CN (1) CN102665684A (enExample)
CA (1) CA2777899C (enExample)
GB (1) GB0918450D0 (enExample)
WO (1) WO2011048379A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
EA036153B1 (ru) * 2012-07-05 2020-10-06 Арвен Айлак Санайи Ве Тиджарет А.С. Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2014105446A1 (en) * 2012-12-27 2014-07-03 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP6827657B2 (ja) * 2012-12-27 2021-02-10 スリーエム イノベイティブ プロパティズ カンパニー 電気化学デバイス及びその作製方法
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
JP2015116367A (ja) * 2013-12-19 2015-06-25 重人 下山 寝具装置、寝具装置制御方法及びプログラム
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
WO2017100656A1 (en) * 2015-12-11 2017-06-15 Otitopic Inc. Dry powder formulations of aspirin for inhalation
WO2019139479A1 (en) * 2018-01-11 2019-07-18 Rob Janssen Compositions and methods for the treatment of lung emphysema and other forms of copd
GB201817861D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
JP2025503459A (ja) * 2021-12-16 2025-02-04 アルヴィアラス バイオ，インコーポレイテッド 疾患の治療のための噴霧乾燥された吸入可能なバイオ治療剤
CN115046816B (zh) * 2022-03-11 2025-09-26 桂林优利特医疗电子有限公司 一种尿液有形成分分析仪用结晶质控物的制备方法
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8802174D0 (en) 1988-02-01 1988-03-02 Quadrant Bioresources Ltd Method of drying macromolecules
AU5414990A (en) 1989-04-12 1990-11-05 Aberdeen University Slow release vitreous systems
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0563455A1 (en) 1992-03-31 1993-10-06 Purac Biochem B.V. Particulate solid products containing a lump forming inhibitor
EP0611567B1 (en) * 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP3095624B2 (ja) 1994-07-19 2000-10-10 株式会社ボッシュオートモーティブシステム 積層型熱交換器の偏平チューブのろう付け方法
ATE252373T1 (de) 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CN1245957C (zh) 1995-06-07 2006-03-22 廓德伦特控股剑桥有限公司 将物质稳定掺入干燥泡沫玻璃基质中的方法以及由此制得的组合物
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9621825D0 (en) 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
WO1999047174A1 (en) 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2003062074A (ja) * 2001-08-29 2003-03-04 Tomohiko Hashiba 吸入装置
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1480996A1 (en) * 2002-02-04 2004-12-01 Glaxo Group Limited Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
WO2003079993A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
JP2005060330A (ja) * 2003-08-18 2005-03-10 Tomohiko Hashiba 球状タンパク質粉体とその製造方法
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
KR20120015295A (ko) * 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
JP5671001B2 (ja) * 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Also Published As

Publication number Publication date
WO2011048379A2 (en) 2011-04-28
EP2490670A2 (en) 2012-08-29
JP2013508344A (ja) 2013-03-07
CN102665684A (zh) 2012-09-12
CA2777899A1 (en) 2011-04-28
GB0918450D0 (en) 2009-12-09
WO2011048379A3 (en) 2012-01-05
US20130004542A1 (en) 2013-01-03
EP2490670B1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
EP2490670B1 (en) Composition for inhalation
EP2429497B1 (en) Process for preparing microparticles
US9011923B2 (en) Suspension formulations
Newman Dry powder inhalers for optimal drug delivery
ES2650663T3 (es) Proceso y producto para inhalación que comprende glicopirrolato
US9907754B2 (en) Taurine compositions suitable for inhalation
JP5318119B2 (ja) 吸入器
JP2011523861A (ja) 吸入器
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
JP5833824B2 (ja) 吸入器
US11672929B2 (en) Product delivery devices and methods
JP2005519095A (ja) 新規製剤
CN111481550A (zh) 含有噻托溴铵和阿福特罗的药物制剂
AU2020356243B2 (en) Novel carrier particles for dry powder formulations for inhalation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140320

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205